Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03560583
NA

Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients

Sponsor: Barzilai Medical Center

View on ClinicalTrials.gov

Summary

Poor ovarian response population of ART are considered the biggest challenge for providers. Hitherto, no one protocol has been proven to be effect in this subgroup of IVF patients. Metoclopramide belongs to the antiemetic group, used for motion sickness and during early gestation for hyperemesis gravidarum. The mechanism of action is antagonisim to dopamine receptors. We hypothesize than by blocking dopamine receptors and decreasing the dopaminergic tone there is a possibility to increase the sensitivity of ovarian response to gonadotropins during controlled ovarian stimulation and result in increased oocyte retrival.

Official title: Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients: a Randomised, Double-blind, Placebo-controlled Trial

Key Details

Gender

FEMALE

Age Range

18 Years - 54 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2021-05-05

Completion Date

2028-07

Last Updated

2025-02-10

Healthy Volunteers

Yes

Interventions

DRUG

Metoclopramide

Metoclopramide 10 mg BID

DRUG

Placebo Oral Tablet

Placebo 10 mg BID

Locations (1)

Barzilai University Medical Center

Ashkelon, Ashkelon District, Israel